Secukinumab earns FDA approval for plaque psoriasis

The U.S. Food and Drug Administration has approved secukinumab for the treatment of moderate to severe plaque psoriasis in adults. The injectable interleukin-17A inhibitor is indicated for...

Field of Interest: Dermatology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.